Research

Research

Two On Lawn1. Goals:

  • To broaden understanding of the clinical course of MS
  • To participate in the development of new treatments for MS
  • To provide research opportunities for patients at all stages of the disease

 

2. Trials for which recruitment is ongoing:

  • Validation of a Motor Fatigue Measure in Multiple Sclerosis. IRB 14610 PI – Myla Goldman, MD
  • A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis IRB 16467PI – Myla Goldman
  • A randomized controlled trial of vitamin D in multiple sclerosis. IRB 16493 PI – David E. Jones, MD
  • A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod. IRB  17093 PI– David E. Jones, MD
  • A study of the relationship between patient –reported outcomes and ambulatory device measurements in multiple sclerosis IRB 1662 8PI – Myla Goldman, MD
  • A measure of insulin resistance in the multiple sclerosis population IRB 16663 PI – Myla Goldman, MD
  • Fatigue in Multiple Sclerosis IRB 16829 PI – Myla Goldman, MD
  • Pilates-based exercise vs. strength training in multiple sclerosis IRB 17077 PI – Myla Goldman, MD

 

3. Trials that are ongoing but not recruiting:

  • A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive MS.  IRB 14115  PI—Myla Goldman MD
  • JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri:  Stratify-2   IRB 15132  PI—Myla D. Goldman MD
  • A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5 mg fingolimod administered orally once daily in patients with MS.  IRB 16128  PI—Myla D. Goldman MD
  • A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive MS.  IRB 15732 PI—Myla Goldman MD 
 

Clinic Home

Mission

Clinical Services

Research

Education

Clinic Team

Directions

Contact Information

How You Can Help

sidebar clinic name big